

**SYDNEY CANCER CONFERENCE 2010 (SCC2010)
EASTERN AVENUE COMPLEX, THE UNIVERSITY OF SYDNEY**

WEDNESDAY 14 JULY 2010

6.30-7.30pm PUBLIC LECTURE: *Can we make lung cancer history? The rise and fall of the smoking epidemic.*

Speaker: Professor Simon Chapman, The University of Sydney
Venue: Eastern Avenue Auditorium
CHAIR: Prof Richard Christopherson

7.30-8.30pm CONFERENCE MIXER

Venue: Eastern Avenue Foyer
Drinks and canapés will be served

THURSDAY 15 JULY 2010

Session 1 - Opening ceremony and plenary session

Venue: Eastern Avenue Auditorium

CHAIR: A/Prof Graham Mann

9.00am Welcome and Introduction

9.05am Opening address by the Minister Assisting the Minister for Health (Cancer)

9.15am Prof David Currow, Chief Cancer Officer and CEO of the Cancer Institute NSW

Address on *The future of cancer research in NSW*

9.45am KEYNOTE ADDRESS

KN01 Prof Charles Cleeland (Uni of Texas, USA)

New directions in cancer symptom research

10.45am MORNING TEA AND POSTER VIEWING

Session 2 - Cancer genetics and risk

Venue: Eastern Avenue Auditorium

CHAIR: Prof Juergen Reichardt

11.15am S001 Dr David Thomas (Peter Mac)

Cancer genetics and sarcomas: The international sarcoma kindred study

11.45am S002 Dr Claire Vajdic (UNSW)

Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency?

12.15pm S003 Ms Kamila Marzec (USyd)

Activation of Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) by DNA-dependent Protein Kinase (DNA-PK) or Ataxia Telangiectasia Mutated (ATM) is not necessary for its proapoptotic functions

Session 3 - Colorectal, thyroid and lung cancer

Venue: Carlaw 173

CHAIR: Prof Michael Solomon

11.15am S004 Prof Robyn Ward (UNSW)

CRC and personalised medicine - Is the cart before the horse?

11.45am S005 Dr Michael Suen (RPAH)

A better way of managing malignant large bowel obstruction

12.05pm S006 Mr Leonardo Simonella (Cancer Council NSW)

Providing optimal evidence based treatment for non-small cell lung cancer improves survival

12.25pm S007 Prof Dianne O'Connell (Cancer Council NSW)

Pathways to diagnosis of thyroid cancer in New South Wales

Session 4 - Screening and cancer vaccines

Venue: Eastern Avenue Lecture Theatre

CHAIR: Prof Glenn Salkeld

11.15am S008 Prof Bruce Armstrong (USyd)

PSA screening for prostate cancer: Early detection or over-detection?

11.45am S009 Ms Rebekah Powell (USyd)

'Is it worth a shot?' Factors influencing uptake of the HPV vaccine amongst young adult women in Australia.

12.15pm S010 Dr Cannas Kwok (USyd)

Development and psychometric testing of a culturally sensitive instrument examining breast cancer screening behaviors among Chinese Australian women

Session 5 - Early phase clinical trials

Venue: Carlaw 273

CHAIR: Prof Philip Hogg

11.15am S011 A/Prof Martin Stockler (USyd)

Making sense of early phase cancer clinical trials: Designs, endpoints and sample sizes

11.45am S012 A/Prof Stephen Mulligan (Kolling/RNSH)

Chronic lymphocytic leukaemia: Novel therapies and clinical trials - Continuation and refinement of the therapeutic revolution

12.15pm S013 Dr David Ziegler (UNSW)

Targeting childhood cancer - From bench to bedside

12.45pm LUNCH AND POSTER VIEWING

Session 6 - Plenary session: Cancer prevention**Venue: Eastern Avenue Auditorium****CHAIR: Prof Bruce Armstrong**

- 2.00pm **S014 A/Prof Elizabeth Eakin** (UQ)
Promoting physical activity in women with breast cancer
- 2.45pm **S015 Dr Anne Cust** (Uni of Melb)
Sun exposure and sunbed use during childhood and early adulthood and melanoma risk before age 40

3.15pm AFTERNOON TEA AND POSTER VIEWING**Session 7 - Cancer targets and treatments****Venue: Eastern Avenue Auditorium****CHAIR: A/Prof Jacqueline Matthews**

- 3.45pm **S016 Prof Peter Hudson** (Avep)
Engineered antibodies optimized for clinical diagnosis and therapy
- 4.15pm **S017 Dr Jennifer MacDiarmid** (EnGenelc)
Tailor made cancer therapeutics: Bacterially-derived non-living nanoparticles for the targeted delivery of drugs and siRNA for potent anti-tumor effects in vivo
- 4.45pm **S018 Prof Roger Reddel** (USyd)
ALT activity in normal cells and cancer

Session 8 - Quality of life and doctor/patient communication**Venue: Carlaw 173****CHAIR: Prof Phyllis Butow**

- 3.45pm **S019 Prof Madeleine King** (USyd)
Health-related quality of life versus needs assessment: Do conceptual distinctions translate empirically?
- 4.15pm **S020 Ms Lynley Aldridge** (USyd)
Health disparities and unmet needs in Chinese (Mandarin and Cantonese), Greek, and Arabic-speaking cancer survivors in New South Wales
- 4.45pm **S021 Ms Mikaela Jorgensen** (USyd)
Older patients and adjuvant therapy for colorectal cancer: Surgeon knowledge, opinions and practice

Session 9 - Late phase clinical trials**Venue: Eastern Avenue Lecture Theatre****CHAIR: Prof Stephen Ackland**

- 3.45pm **S022 Prof John Simes** (USyd)
Profiling risk, personalising treatment and predicting outcomes: the role of clinical trials
- 4.15pm **S023 Dr Mirko Essing** (Fresenius Biotech, Germany)
Catumaxomab (Removab) for the treatment of malignant ascites
- 4.45pm **S024 Prof Stephen Ackland** (Univ of Newcastle)
Increasing capacity in value-added clinical trials in Australia

Session 10 - Breast, ovarian and prostate cancer**Venue: Carlaw 273****CHAIR: Dr Rosemary Balleine**

- 3.45pm **S025 A/Prof Freddy Sitas** (Cancer Council NSW)
A follow up of a breast cancer cluster among Australian Broadcasting Corporation female employees in Australia
- 4.05pm **S026 Mr Rajah Supramaniam** (Cancer Council NSW)
Beyond access: Is Aboriginality a risk factor for survival after breast cancer?
- 4.25pm **S027 Dr Richard Morgan** (Uni of Surrey)
Engrailed-2 (EN2): A highly specific urinary biomarker for the early diagnosis of prostate cancer
- 4.45pm **S028 Ms Kylie Pryor** (USyd)
Ankyrin Repeat Domain Protein 1 (ANKRD1) is expressed in all major ovarian cancer subtypes and expression level is related to cisplatin sensitivity in ovarian cancer cell lines

6.30- CONFERENCE DINNER**10.30pm** Venue: The Great Hall, The University of Sydney

Session 11 - Plenary session - Biomarkers in cancer**Venue: Eastern Avenue Auditorium****CHAIR: Prof John Simes**9.00am **KEYNOTE ADDRESS****KN02 Prof Patrick Bossuyt** (Uni of Amsterdam, the Netherlands)*Evaluating biomarkers for therapy selection*10.00am **S029 Prof Matt Trau** (UQ)*Biomarkers & nanotechnology: New approaches to preventative and personalised medicine*10.45am **MORNING TEA AND POSTER VIEWING****Session 12 - Molecular mechanisms of cancer I****Venue: Eastern Avenue Auditorium****CHAIR: Prof Rob Baxter**11.15am **S030 Prof Suzanne Cory** (WEHI)*The BCL-2 life/death switch in cancer development and therapy*11.45am **S031 A/Prof Andrew Roberts** (WEHI)*Exploiting BCL-2 overexpression for therapeutic gain in lymphoid malignancies: preclinical and clinical approaches*12.15pm **S032 Ms Zeenia Kaul** (USyd)*Spontaneous telomere dysfunction and senescence in primary human cells***Session 13 - Proteins and cancer****Venue: Carlaw 173****CHAIR: Prof Mark Baker**11.45am **S033 Prof Mark Baker** (Macquarie Uni)*Membrane proteome interactions and colorectal cancer metastasis*12.10pm **S034 Ms Thi Thanh Vu** (USyd)*The role of Krüppel-like factor 3 in B-lymphocyte development and tumorigenesis*12.30pm **S035 Dr Nicole Verrills** (Uni of Newcastle)*Targeting the tumour suppressor, PP2A, as a novel therapy for acute myeloid leukaemia***Session 14 - Prognostic research****Venue: Carlaw 273****CHAIR: A/Prof Nehmat Houssami**11.45am **S036 A/Prof Andrew Spillane** (USyd)*Lymph node ratio provides prognostic information in addition to AJCC N stage in patients with melanoma, even if quality of surgery is standardized*12.05am **S037 Dr Steven Kao** (Sydney Cancer Centre)*Validation of blood neutrophil-to-lymphocyte ratio as a prognostic factor in patients with malignant mesothelioma undergoing chemotherapy*12.25pm **S038 Dr David Chang** (Garvan Institute)*A preoperative prognostic nomogram for pancreatic cancer using molecular biomarkers***Session 15 - Supportive cancer care****Venue: Eastern Avenue Lecture Theatre****CHAIR: Prof Kate White**11.15am **S039 Prof Afaf Girgis** (Uni of Newcastle)*Flourishing or flailing? The impact of cancer on survivors and their caregivers*11.45am **S040 Dr Claire Wakefield** (Sydney Children's Hospital)*Perceptions of support received and needed by young people who have recently completed cancer treatment and their families*12.05pm **S041 Dr Jordana McLoone** (UNSW)*Psychosocial adjustment and support needs of melanoma survivors receiving care at a high risk clinic: A qualitative investigation*12.25pm **S042 Ms Joanna Fardell** (USyd)*Exercise ameliorates oxaliplatin and 5-fluorouracil induced cognitive deficits in laboratory rodents*12.45pm **LUNCH AND POSTER VIEWING****Session 16 - Plenary session****Venue: Eastern Avenue Auditorium****CHAIR: Prof Roger Reddel**2.00pm **KEYNOTE ADDRESS****KN03 Dr Nadia Zaffaroni** (National Cancer Institute, Italy)*MicroRNAs in prostate cancer: A possible role as novel biomarkers and therapeutic targets?*2.45pm **S043 Prof Doug Hilton** (WEHI)*Pathways regulating blood cell production*3.15pm **AFTERNOON TEA AND POSTER VIEWING**

Session 17 - Melanoma and brain cancer

Venue: Eastern Avenue Auditorium

CHAIR: Prof Rick Kefford

- 3.45pm **S044 Prof Brandon Wainwright** (UQ)
Medulloblastoma is controlled by an interaction between genetic pathways important in embryonic development
- 4.10pm **S045 A/Prof Graham Mann** (USyd)
Are biomarkers beginning to make a difference in melanoma?
- 4.35pm **S046 Dr Katie Ashton** (Uni of Newcastle)
Base excision repair and gene expression profiling in malignant melanoma

Session 18 - Molecular mechanisms of cancer II

Venue: Eastern Avenue Lecture Theatre

CHAIR: Prof Madeleine King

- 3.45pm **S047 Dr Chris Scarlett** (Garvan Institute)
S100A2 calcium-binding protein expression defines a specific pancreatic cancer phenotype and plays a key role in metastasis
- 4.10pm **S048 Dr Honor Hugo** (St Vincents Institute of Medical Research, Melbourne)
Snail2 transcriptionally represses c-Myb in EMT
- 4.35pm **S049 Dr Maija Kohonen-Corish** (Garvan Institute)
A novel function of MCC in the DNA damage response

Session 19 - Consumer involvement in research

Venue: Carslaw 173

CHAIR: A/Prof Fran Boyle

- 3.45pm **S050 A/Prof Maureen Boughton** (USyd)
Being diagnosed with acute lymphoblastic leukaemia at the age of 22: A critique of the experience and encounters with health professionals
- 4.10pm **S051 Dr Monica Robotin** (USyd/Cancer Council NSW)
Lessons from the field: Engaging consumers in the fight against cancer
- 4.35pm **S052 Sally Crossing** (Cancer Voices NSW)
Consumer Involvement in Research (CIR)

Session 20 - Cancer therapeutics

Venue: Carslaw 273

CHAIR: Prof Stephen Clarke

- 3.45pm **S053 Dr Sutharshani Sivagurunathan** (USyd)
The metastasis suppressor NDRG1 up-regulates the potent cyclin dependent kinase inhibitor, P21 in cancer cells via transcriptional and post-transcriptional mechanisms
- 4.10pm **S054 Ms Noor Al-Dasooqi** (Uni of Adelaide)
Matrix metalloproteinases play a pivotal role in the development of alimentary tract mucositis
- 4.35pm **S055 Ms Junggha Kim** (USyd)
Towards more effective breast cancer radiotherapy

5.00pm Session 21: PANEL DISCUSSION - "TRANSLATING CANCER RESEARCH"

Venue: Eastern Avenue Auditorium

CHAIR: Prof John Shine

5.40pm CLOSING CEREMONY AND AWARDS PRESENTATION

Venue: Eastern Avenue Auditorium

CHAIR: Prof Richard Christopherson

5.50pm FINISH**CODING**

- Plenary
- Basic biomedical
- Clinical
- Public health
- Psychosocial
- Mixed session